← Eichor
Study identifier: NCT07281898 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Burst Stimulation for Paroxysmal Atrial Fibrillation

Condition: Paroxysmal Atrial Fibrillation  ·  Sponsor: Zhibing Lu

PhaseNA
Planned participants240
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

Atrial fibrillation (AF) is one of the most common cardiac arrhythmias worldwide, associated with high morbidity and mortality rates. Epidemiological studies in China show that the prevalence of AF in individuals aged ≥60 years ranges from 2% to 3%, with rates continuing to rise due to population aging. Paroxysmal atrial fibrillation (PAF), if inadequately controlled, tends to progress to persistent AF, significantly increasing the risk of stroke, heart failure, and death. Catheter ablation has become a first-line therapy for drug-refractory PAF, with pulmonary vein isolation (PVI) recognized as the cornerstone procedure. However, multiple prospective studies and meta-analyses indicate that long-term recurrence rates following PVI alone remain as high as 30%-50%. This observation has prompted researchers to investigate the roles of non-pulmonary vein triggers, atrial remodeling, and electrophysiological substrate in PAF recurrence. The superior vena cava (SVC) has been identified as a common non-pulmonary vein trigger, with empirical SVC isolation demonstrating additional clinical benefits in select studies. Furthermore, the presence of atrial electrical remodeling and reentry-dependent substrate suggests that trigger-focused ablation strategies alone may be insufficient to prevent recurrence in certain PAF patients. Burst pacing-induced atrial tachyarrhythmias, such as atrial flutter or fibrillation, provide a practical method for assessing atrial substrate. Retrospective st…

This description comes directly from the study's public registry record.

Talk to the study team

Zhibing Lu  ·  027-67812783  ·  luzhibing222@163.com

Always discuss trial participation with your own doctor first.

Locations (3)

Zhongnan Hospital of Wuhan UniversityWuhan, Hubei, ChinaRecruiting
Xiangyang Central HospitalXiangyang, Hubei, ChinaRecruiting
Yichang Central People's HospitalYichang, Hubei, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07281898